Health TrialsbyHealthPanel

Local Inflammation in Arrhythmogenic Right Ventricular Cardiomyopathy

ConditionArrhythmogenic Right Ventricular Dysplasia
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-99
SponsorUniversity Hospital, Toulouse

About this trial

The understanding of ARVC pathophysiology remains incomplete. Several clues indicate that disease progression is mediated through inflammation. The present study aim to document the feasibility of detecting the potential presence of intracardiac local inflammatory components in patients with ARVC.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Arrhythmogenic right ventricular dysplasia diagnosed (according to 2010 Task Force Criteria)

Admitted for right ventricle electrophysiologic mapping

For controls * Admitted for ablation procedures (accessory pathway, atrial flutter) on otherwise healthy hearts.

Disqualifiers

Diagnostic of systemic chronic inflammatory disease

Presence of possible or proven cardiac involvement of an inflammatory disease, an acute or chronic infectious disease.

Taking immunosuppressant or immunomodulating medications

Trial design

Design model

Parallel

Treatments tested in this trial

  • Peripheral immunological assessment on venous blood

    Biological/Vaccine

    Peripheral immunological assessment carried out as part of the research, on venous blood at the puncture point necessary for the electrophysiological examination: 1 heparin tube and 1 EDTA tube

  • Immunological assessment carried out on intracardiac material

    Biological/Vaccine

    Immunological assessment carried out as part of the research, on intracardiac material taken during the electrophysiological examination: 1 EDTA tube

Treatment groups

80 Participants
are divided into 2 treatment groups
Group A: PatientsExperimental treatment 2 interventions
Group B: Control caseExperimental treatment 2 interventions

Trial outcomes

Primary outcomes

1

Identify the inflammatory components by C-reactive protein

Rate of C-reactive protein in the blood

Time frame
24 months
2

Identify the inflammatory components by interleukine1

Rate of interleukin 1 beta in the blood

Time frame
24 months
3

Identify the inflammatory components by onterleukine6

Rate of interleukin 6 in the blood

Time frame
24 months
4

Identify the inflammatory components by interleukine10

Rate of interleukin 10 in the blood

Time frame
24 months

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

University Hospital, Toulouse

Lead sponsor

Source ClinicalTrials.gov
Apply now